Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 14/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15972558 | 0.86 | FFAR1 (0.38) | FFAR1ALDH1A1MAPTHTT | |
| SCHEMBL16318969 | 0.86 | PDE4A (0.44) | FFAR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15972559 | 0.86 | FFAR1 (0.38) | FFAR1ALDH1A1MAPTHTT | |
| SCHEMBL17408847 | 0.84 | TUBB4A (0.42) | FFAR1MAPT | |
| SCHEMBL16319076 | 0.84 | TUBB4A (0.42) | FFAR1MAPT | |
| SCHEMBL30533371 | 0.84 | FFAR1 (0.39) | FFAR1SLC6A2SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL17413839 | 0.82 | TYR (0.48) | FFAR1ALDH1A1MAPTHTT | |
| SCHEMBL15973236 | 0.81 | ADRB2 (0.36) | FFAR1SLC6A3ALDH1A1MAPTHTT | |
| SCHEMBL17493566 | 0.81 | ADRB2 (0.46) | ADRB1ADRB3FFAR1 | |
| SCHEMBL13715262 | 0.80 | FFAR1 (0.48) | FFAR1ALDH1A1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181186-B2 | Aromatic ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-10 | — | — | US | disclosed |
| US-20150045378-A1 | AROMATIC RING COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-12 | — | — | US | disclosed |
| EP-2816032-A1 | AROMATIC RING COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045378-A1 | AROMATIC RING COMPOUND | GPR119, GPR27, GPR4 | ADRB1 19/4885ADRA2A 95/4885ADRB3 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.